Charles River to Acquire Frontage Units for Up to $545 Million

By Nathan Brooks

Charles River Laboratories has entered definitive agreements to acquire Frontage Holdings Corporation’s bioanalysis and drug metabolism and pharmacokinetics businesses in Exton, Pennsylvania, for a total of up to approximately $545 million.

The consideration includes approximately $470 million in cash and additional payments of up to $75 million, contingent on future performance. Charles River said the deal expands its clinical bioanalysis capabilities and supports the Pathway to Purpose strategy.

The company describes Pathway to Purpose as strengthening scientific services and expanding support across the drug development lifecycle. The acquisition also gives Charles River a larger role in supporting pharmaceutical and biotechnology customers throughout development.

What does the acquisition change for drug developers?

Charles River says drug developers can work with one provider across more of the testing pathway, from early research into clinical trials. The acquired Frontage operations add bioanalytical testing, biomarker analysis and DMPK services alongside Charles River’s established preclinical bioanalysis capabilities.

Charles River expects customers to work with a more integrated scientific services provider as drug candidates advance. The company believes this continuity across development can improve client relationships.

Charles River said pharmaceutical and biotechnology companies use the acquired services when evaluating investigational treatments. The operation supports large and small molecules, with particular emphasis on testing conducted during clinical development.

Charles River said the acquired business spans two Exton facilities totaling approximately 150,000 square feet and employing about 340 people. One laboratory is certified under the Clinical Laboratory Improvement Amendments.

Birgit Girshick, CEO of Charles River Laboratories, said:

“The planned acquisition accelerates our strategy to expand our bioanalysis capabilities and enhance our offering in an attractive, high-growth market. As biologics and increasingly complex modalities become a larger part of development pipelines, clients are seeking scientific partners that can support programs from early development through the clinic.”

“By adding Frontage’s clinical bioanalysis expertise, talented scientific team, and strong client relationships, we will be better positioned to meet those evolving needs.”

Charles River said clinical-stage testing currently generates approximately 15% of its bioanalysis revenue. The acquired operations should expand that business and let the company support customers as drug candidates move from early research into clinical trials.

Biologics and complex therapeutic modalities currently account for approximately 75% of Charles River’s bioanalysis revenue, the company said. It expects demand for specialized testing methods and advanced analytical techniques used throughout development to increase as these therapies represent a growing share of pharmaceutical development programs.

Girshick added:

“This acquisition will advance our Pathway to Purpose strategy by expanding our presence in clinical bioanalysis, strengthening our scientific leadership, and enhancing our ability to serve clients across the drug development lifecycle. Our combined bioanalysis and DMPK offering will provide a more integrated solution that accelerates development timelines and improves continuity from preclinical through clinical testing.”

“The transaction is expected to enhance our growth profile and support long-term value creation for clients and shareholders. We look forward to welcoming Frontage’s talented bioanalysis and DMPK team to the Charles River family.”

Charles River expects stronger growth in clinical-stage testing and complex therapeutic modalities. It also expects the acquired businesses to grow at a rate consistent with the broader bioanalysis market over the next five years.

According to market estimates cited by Charles River, the global bioanalysis sector could expand from approximately $6 billion in 2026 to between $8 billion and $9 billion by 2031. That represents projected annual growth of approximately 6% to 8%.

Based on Charles River’s figures, the acquired Frontage operations represented approximately 40% of Frontage’s $256.7 million in total revenue during 2025. Put another way, they represent roughly two-fifths of Frontage’s 2025 revenue base.

How the transaction is structured

The acquisition is part of a broader restructuring of Frontage Holdings Corporation, which is listed on the Hong Kong Stock Exchange, according to Charles River. Charles River is participating in an acquisition consortium with Hongkong Tigermed, a subsidiary of Hangzhou Tigermed Consulting, and Frontage Chairman Dr. Song Li.

The acquisition consortium intends to privatize Frontage through a court-sanctioned scheme of arrangement. Under the consortium’s plan, Frontage’s businesses will be separated into different subsidiaries after privatization.

Charles River will retain the Exton-based bioanalysis and DMPK operations. Frontage’s other businesses will be transferred to Tigermed, Dr. Song Li or their affiliates.

Charles River said the transaction remains subject to shareholder, regulatory and court approvals. The company expects completion during the first half of 2027.

It said the acquired operations will increase Charles River’s clinical testing capacity and expand its role supporting pharmaceutical and biotechnology customers throughout drug development. Charles River plans to finance the acquisition with available cash and its credit facility.

The company expects the transaction to leave 2027 non-GAAP earnings per share neutral and to become accretive thereafter, meaning it should add earnings per share after 2027. J.P. Morgan and CICC are serving as joint financial advisors to the acquisition consortium, Charles River said.

Charles River’s forecast ultimately depends on stronger growth in clinical-stage testing, now about 15% of bioanalysis revenue. It also expects demand for complex-modality testing, already about 75% of the mix, to rise as those therapies take a larger share of development programs.